Drugs News and Research

RSS

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Idenix third quarter total revenue increases from $3.1 million to $3.8 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2010.

30 Oct 2010

Drug and device makers face new taxes, fees

A Fox Business report shows the health overhaul is cutting deeper into drug and device makers' profits than many expected. Research & development programs are already being drastically scaled back.

30 Oct 2010

ACRO responds to government report on FDA's Overseas Offices

The Association of Clinical Research Organizations, which represents the global CRO industry, issued the following statement in response to the Government Accountability Office's report on the Food and Drug Administration's Overseas Offices.

29 Oct 2010

NCI indifferent to, or unaware, of avoidable non-smoking causes of lung cancer, says coalition

“You can't do experiments to see what causes cancer--it's not an accessible problem, and not the sort of thing scientists can afford to do--everything you do can't be risky.”

29 Oct 2010

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Healthcare costs expected to reach $191.6 billion in 2010

Total spending on health care in Canada is expected to reach $191.6 billion this year, growing an estimated $9.5 billion, or 5.2%, since 2009, according to new figures released today by the Canadian Institute for Health Information (CIHI).

29 Oct 2010

Pepsi Refresh grant helps in launching Rett syndrome drug development program

The International Rett Syndrome Foundation (IRSF) believes that accelerating the pace of meritorious research, supporting families, and raising awareness are the minimum effort necessary to successfully search for treatments and a cure for one of the most devastating neurological diseases to affect young girls. On October 1, IRSF became the recipient of a $250,000 grant from the Pepsi Refresh contest that was officially confirmed later in the month.

29 Oct 2010

Inadequate payments prompt insurance companies to raise premiums, avoid low-income market

Millions of Medicare recipients have been forcibly reassigned to different prescription drug plans because Part D reimbursements to insurance companies covering low-income patients are lower than the actual costs incurred, according to a study released online today by Health Affairs. The report describes how a system designed to encourage competition and to subsidize care for low-income Medicare patients instead has led companies to raise their premiums in an effort to price themselves out of the low-income segment of the Part D market.

29 Oct 2010

Researchers identify novel mechanism in control of cell motility

A team of scientists at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Jean-Fran-ois C-t-, Director of the Cytoskeletal Organization and Cell Migration research unit, identified a novel molecular mechanism in the control of cell motility. Their findings were published online today in Current Biology, a journal from the Cell Press group. This scientific breakthrough could eventually lead to the development of new cancer-treating drugs that could block the spread of tumours (metastasis).

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

Maxygen sells MolecularBreeding platform technology to Codexis for $20M

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that it has sold its MolecularBreeding™ platform technology to Codexis, Inc. for $20 million in cash.

29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

PHARMABIZ.com examines India’s push for clearer definition of counterfeit, substandard medicines

India has taken the lead to get together a number of generic drug-producing nations to call for better definitions to ensure quality, strengthening of regulatory authorities in the respective countries, and bringing focus of the world to public health instead of intellectual property, PHARMABIZ.com writes in an article that examines the recent meeting of leaders from Brazil, India and South Africa on issues regarding counterfeit medicines.

29 Oct 2010

Study finds site of tumor impacts disease stage in head and neck cancer

Developing a molecular fingerprint for head and neck cancer tumors could help improve diagnosis and treatment for this deadly and often-times disfiguring form of cancer, according to researchers at Henry Ford Hospital in Detroit.

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

The first national outcome-based contract between a pharmaceutical company and a pharmacy benefit management company resulted in an increase in the number of people with type 2 diabetes who were able to control their blood sugar levels by taking their medications appropriately.

29 Oct 2010

Researchers depict new statistical algorithm to identify genetic variations for common diseases

A group of researchers at The Scripps Research Institute and the Scripps Translational Science Institute has published a paper that reviews new strategies for identifying collections of rare genetic variations that reveal whether people are predisposed to developing common conditions like diabetes and cancer.

29 Oct 2010

With incentives from insurers, pharmacies refocus from snacks to drugs

Drug stores are returning to their roots — drugs, the (Raleigh N.C.) News and Observer/Scripps News reports. "After years of adding everything from groceries to grills to their inventory, drugstore chains are once again emphasizing their pharmacies.

29 Oct 2010

Drugs News and Research

Teflaro receives FDA approval for treatment of bacterial infections

Idenix third quarter total revenue increases from $3.1 million to $3.8 million

Drug and device makers face new taxes, fees

ACRO responds to government report on FDA's Overseas Offices

NCI indifferent to, or unaware, of avoidable non-smoking causes of lung cancer, says coalition

Mechanism that controls embryonic development could also prevent cancer

Novel small molecule inhibitors may provide new therapy for colon cancer

Healthcare costs expected to reach $191.6 billion in 2010

Pepsi Refresh grant helps in launching Rett syndrome drug development program

Inadequate payments prompt insurance companies to raise premiums, avoid low-income market

Researchers identify novel mechanism in control of cell motility

International Congress at Spain highlights advances in neuroimmunological disease treatment

Maxygen sells MolecularBreeding platform technology to Codexis for $20M

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

PHARMABIZ.com examines India’s push for clearer definition of counterfeit, substandard medicines

Study finds site of tumor impacts disease stage in head and neck cancer

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

Researchers depict new statistical algorithm to identify genetic variations for common diseases

With incentives from insurers, pharmacies refocus from snacks to drugs

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News